https://www.selleckchem.com/peptide/gsmtx4.html
e., flap failure) and minor (i.e., seroma) complications, and length of stay (LOS). Overall, 777 patients underwent ABR (ERAS 312 and pre-ERAS 465). ERAS patients received significantly less total fluid volume (ERAS median 3750 mL [IQR 3000-4500 mL]; pre-ERAS median 5000 mL [IQR 4000-6400 mL]; and p0.001), had lower UOP, were more likely to receive vasopressor agents (47% vs 35% and p0.001), and had lower LOS (ERAS 4 days [4-5]; pre-ERAS 5 [4-6]; and p0.001) as compared to pre-ERAS patients. Complications did not differ betwee
Gefällt mir
Kommentar
Teilen
